摘要
目的 观察孟鲁司特 (顺尔宁 )的临床疗效和安全性。方法 非急性发作期的轻中度哮喘患者口服孟鲁司特8周 ,其他治疗措施维持不变 ,观察治疗前后症状体征评分、FEV1 和 PEFR变化、β2 受体激动剂用量等指标。结果 治疗后 30例哮喘患者的症状体征评分及自我评价均有显著改善 ,FEV1 由 6 7%增加至 85 % ,PEFR%由 5 8%增加至 82 % ,β2受体激动剂用量由每周 18喷减少到 11喷。孟鲁司特的不良反应轻微 ,患者均能良好耐受。结论 孟鲁司特使用方便 ,安全性高 ,对非急性发作期哮喘患者能较好地控制症状、预防复发 ,尤对夜间哮喘效果良好 ,并有助于减少β2
Objective To study the efficacy and safety of Montelukast in the long term therapeutic schedule for asthmatics. Methods Asthmatic patients without acute attack received a regiment of oral montelukast for 8 weeks.The symptom sign scores, improvements of FEV 1 and PEFR,decrement of utility of β 2 agonist were evaluated before and after treatment. Results 30 subjects receiving montelukast exhibited significant improvement in symptom sign scores,FEV 1,PEFR,dose of β 2 agonist.Mild adverse effects were observed,while most subjects tolerated them without withdraw from the clinical trial.Conclusions Montelukast is a safe and effective agent for control of exacerbation and improvement of lung function,especially in nocturnal asthma,meanwhile the dose of β 2 agonist or corticoids could be reduced by combination with montelukast.
出处
《四川医学》
CAS
2002年第4期333-334,共2页
Sichuan Medical Journal
